Polyclonal · Monoclonal · Recombinant
Hybridoma & Phage Display
Full Characterization
Conjugation Services
GMP-Grade Available
Service Overview
End-to-End Antibody Development, From Antigen to Application
ICDMO's antibody development platform integrates immunology expertise, advanced hybridoma technology, phage display, and recombinant expression to deliver custom antibodies of exceptional quality. Whether your goal is a research-grade polyclonal serum, a hybridoma-derived monoclonal for diagnostic standardization, or a sequence-defined recombinant IgG for therapeutic development, our team manages every step from antigen design through application validation.
Every antibody project is supported by rigorous titer monitoring, specificity confirmation, and application-specific validation. We offer optional epitope mapping, affinity measurement (SPR/BLI), isotype determination, and conjugation services to deliver a fully characterized antibody ready for your intended use.
500+
Antibodies Developed
10+
Host Species
6+
Antibody Formats
Antibody Types
Three Core Antibody Platforms
Each platform is supported by dedicated scientists with deep immunology and protein engineering expertise.
What We Offer
Immunization & Antigen Preparation
▸Recombinant protein, peptide conjugate (KLH/BSA), DNA, cell, and VLP antigens accepted
▸Custom antigen design and production service available if required
▸Multi-species immunization: rabbit, mouse, rat, goat, sheep, guinea pig, chicken
▸Adjuvant selection (CFA/IFA, TiterMax, Freund's) optimized per antigen type
▸Immunization schedule design: 3-injection or 4-injection protocol with titer monitoring by ELISA
Hybridoma Development & Screening
▸Spleen fusion with SP2/0 or P3X63 myeloma cells using PEG or electrofusion
▸HAT selection and primary screening by ELISA within 3 weeks of fusion
▸Secondary screening: specificity (Western blot, IF, FC, IHC) and isotype determination
▸Subcloning by limiting dilution: minimum 2 rounds to ensure monoclonality
▸Stable hybridoma banking: cryopreservation of ≥5 vials per confirmed clone
Antibody Production & Purification
▸Ascites production (murine/rat) or roller bottle / bioreactor cell culture
▸Protein A/G affinity purification → dialysis into PBS or custom buffer
▸Optional: Fab / F(ab')₂ fragmentation by papain/pepsin digestion
▸IgG, IgM, IgA, IgY isotypes; subclass-specific secondary antibody available
▸Conjugation: HRP, biotin, FITC, PE, APC, Alexa Fluor dyes, quantum dots
Antibody Characterization
▸Titer determination by direct and indirect ELISA
▸Affinity measurement: KD by SPR (Biacore), BLI (Octet), or ELISA-based titration
▸Specificity panel: Western blot (denaturing / native), dot blot, immunoprecipitation
▸Application validation: IHC (FFPE & frozen), IF/ICC, flow cytometry, ELISA, ChIP
▸Epitope mapping: overlapping peptide ELISA, alanine scanning, hydrogen-deuterium exchange
Key Advantages
Broad Host Species
Rabbit, mouse, rat, goat, sheep, guinea pig, chicken, and llama for VHH nanobody development.
Proven Hybridoma Platform
Over 500 monoclonal antibodies generated with guaranteed delivery of ≥3 antigen-positive clones per project.
Phage Display Option
Human or llama antibody libraries for generation of fully human or VHH antibodies without animal immunization.
Complete Characterization
Affinity (KD by SPR/BLI), epitope mapping, isotyping, and multi-application validation all in-house.
Conjugation Services
HRP, biotin, FITC, PE, APC, Alexa Fluor, quantum dot, and custom conjugation with guaranteed lot consistency.
GMP-Grade Production
Therapeutic antibody production in cGMP facility with full batch records and regulatory documentation.
Development Workflow
1
Project Consultation & Antigen Review
Submit your antigen information (sequence, structure, target epitope, intended application). Our scientists assess immunogenicity and recommend immunization strategy and host species.
2
Antigen Preparation
Recombinant protein expression or peptide synthesis. Peptides coupled to KLH/BSA carrier. QC by SDS-PAGE and endotoxin testing before immunization.
3
Animal Immunization & Titer Monitoring
Immunization in selected host species. Serum collected at defined intervals and titer verified by ELISA. Booster injections until target titer achieved (typically ≥1:10,000).
4
Hybridoma Fusion & Primary Screening (mAb only)
Spleen cell fusion, HAT selection, and ELISA primary screening of ~1,000 clones. Positive wells identified within 2–3 weeks of fusion.
5
Secondary Screening & Subcloning
Specificity confirmation by Western blot, IF, or FC. Two rounds of limiting dilution subcloning to ensure monoclonality. Isotype determination by lateral flow assay.
6
Antibody Production, Purification & QC
Scale-up in bioreactor or ascites. Protein A/G purification to >95% purity. Final QC: SDS-PAGE, Western blot, ELISA titer, endotoxin. CoA and sequence report delivered.
Service Process
1
Project Consultation
›
2
Antigen Preparation
›
3
Immunization
›
4
Screening & Cloning
›
5
Production & QC
Specifications & Timeline
Note: All timelines are estimates for standard projects. Complex antigens or low-immunogenicity targets may require additional immunization rounds. For GMP-grade therapeutic antibody production, please contact us for a customized development plan.
Get a Custom Quote
Antibody scientists respond within 24 hours with a tailored development plan and pricing.
Contact Us Online ConsultationStandard Deliverables
✓Purified antibody (specified qty)
✓ELISA titer report
✓SDS-PAGE under reducing conditions
✓Western blot validation
✓Isotype determination
✓Certificate of Analysis (CoA)
✓Stable hybridoma vials (mAb projects)
Why ICDMO?
19+ Years Immunology Experience
500+ Custom Antibodies Delivered
Hybridoma + Phage Display Platforms
In-House Characterization Suite
GMP Facility Available